Note 9 - Earnings Per Share

6 Months Ended

Jun. 30, 2013

Earnings Per Share [Abstract]

Earnings Per Share [Text Block]

9.   EARNINGS PER SHARE

We have adopted the provisions of FASB’s guidance for determining whether instruments granted in share-based payment transactions are participating securities.  The guidance requires that all outstanding unvested share-based payment awards that contain nonforfeitable rights to dividends or dividend equivalents (such as restricted stock awards granted by us) be considered participating securities.  Because restricted stock awards are participating securities, we are required to apply the two-class method of computing basic and diluted earnings per share (the “Two-Class Method”).

Basic earnings per share (“EPS”) is determined using the Two-Class Method and is computed by dividing earnings attributable to Ultralife common shareholders by the weighted-average shares outstanding during the period.  The Two-Class Method is an earnings allocation formula that determines earnings per share for each class of common stock and participating security according to dividends declared and participation rights in undistributed earnings.  Diluted EPS includes the dilutive effect of securities, if any, and reflects the more dilutive EPS amount calculated using the treasury stock method or the Two-Class Method.  For the three and six month periods ended June 30, 2013 and July 1, 2012, both the Two-Class Method and the treasury stock method calculations for diluted EPS yielded the same result.

The computation of basic and diluted earnings per share is summarized as follows:

	Three Month Period Ended						Six Month Period Ended
	June 30,  2013			July 1,  2012			June 30,  2013			July 1,  2012
Net Loss from continuing operations attributable to Ultralife	$	(1,953	)	$	(3,216	)	$	(1,783	)	$	(4,647	)
Net Loss from continuing operations attributable to participating securities (unvested restricted stock awards) (-0-, -0-, -0- and -0- shares, respectively)		-			-			-			-
Net Loss from continuing operations attributable to Ultralife common shareholders (a)		(1,953	)		(3,216	)		(1,783	)		(4,647	)
Effect of Dilutive Securities		-			-			-			-
Net Loss from continuing operations attributable to Ultralife common shareholders - Adjusted (b)	$	(1,953	)	$	(3,216	)	$	(1,783	)	$	(4,647	)
Net Income (Loss) from discontinued operations attributable to Ultralife common shareholders (c)	$	(120	)	$	49		$	144		$	(22	)
Effect of Dilutive Securities		-			-			-			-
Net Income (Loss) from discontinued operations attributable to Ultralife common shareholders - Adjusted (d)	$	(120	)	$	49		$	144		$	(22	)
Average Common Shares Outstanding – Basic (e)		17,459,000			17,396,000			17,458,000			17,376,000
Effect of Dilutive Securities: Stock Options / Warrants		-			-			-			-
Average Common Shares Outstanding – Diluted (f)		17,459,000			17,396,000			17,458,000			17,376,000
EPS – Basic (a/e) - continuing operations	$	(0.11	)	$	(0.18	)	$	(0.10	)	$	(0.27	)
EPS – Basic (c/e) - discontinued operations	$	(0.01	)	$	0.00		$	0.01		$	(0.00	)
EPS – Diluted (b/f) - continuing operations	$	(0.11	)	$	(0.18	)	$	(0.10	)	$	(0.27	)
EPS – Diluted (d/f) - discontinued operations	$	(0.01	)	$	0.00		$	0.01		$	(0.00	)

There were 2,289,538 and 2,363,928 outstanding stock options and awards at June 30, 2013 and July 1, 2012, respectively, that were not included in the three month EPS calculation as the effect would be anti-dilutive.

There were 2,289,538 and 2,363,928 outstanding stock options and awards at June 30, 2013 and July 1, 2012, respectively, that were not included in the six month EPS calculation as the effect would be anti-dilutive.